What is Selank?
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro), engineered as a stable analog of tuftsin with an added Pro-Gly-Pro fragment to improve metabolic stability and duration of action (Volkova et al. 2016). Molecular studies have shown that Selank modulates gene expression linked to neurotransmission, particularly within the GABAergic system. In rat models, it altered transcription of multiple GABAA receptor subunits and transporters, consistent with allosteric modulation of GABAA receptors rather than direct agonism. This regulatory influence extends beyond GABA, with observed effects on dopamine and serotonin receptor pathways, supporting its classification as a multifunctional neuropeptide regulator (Volkova et al. 2016).
Experimental data further demonstrate that Selank produces effects comparable to classical benzodiazepines and can potentiate the anxiolytic action of diazepam under stress conditions, suggesting shared molecular targets at GABAA receptors (Kasian et al. 2017). Clinical research additionally characterizes Selank as a tuftsin analog with neurometabolic and regulatory actions on monoamine turnover, associated with stabilization of excitatory–inhibitory balance and modulation of emotional–cognitive processes (Verbenko & Verbenko 2018). Together, these findings position Selank as a synthetic regulatory peptide with complex, system-level activity mediated through GABAergic and monoaminergic mechanisms.
References
Kasian, A., Kolomin, T., Andreeva, L., Bondarenko, E., Myasoedov, N., Slominsky, P., & Shadrina, M. (2017). Peptide Selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. Behavioural Neurology, 2017, 1–6. https://doi.org/10.1155/2017/5091027
Verbenko, G., & Verbenko, V. (2018). The effectiveness of Selank in the treatment of adjustment disorder. Psychosomatic Medicine and General Practice, 3(1), 1–7. https://doi.org/10.26766/pmgp.v3i1.86
Volkova, A., Shadrina, M., Kolomin, T., Andreeva, L., Limborska, S., Myasoedov, N., & Slominsky, P. (2016). Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Frontiers in Pharmacology, 7, 31. https://doi.org/10.3389/fphar.2016.00031













